AustriaAustria

Hypoallergenic Vaccine may Ease Birch Pollen Allergies

09.10.2004

Vienna - A hypoallergenic vaccine derived from genetically engineered birch pollen can reduce patients' allergic response to the pollen, according to Austrian researchers. A research team around Rudolf Valenta engineered the main birch pollen antigen, Bet v1, to be hypoallergenic and used it for vaccination of 124 patients over the course of one year. Individuals received the vaccine once before the peak of the birch pollen season, and were then screened throughout the year for IgE antibodies that cause allergic reactions by releasing inflammation mediators.
The immunologists found a 50% decrease in both IgE antibody and IgE memory cells together with a significant improvement of symptoms and increased levels of so-called IgG antibodies. They also found that the IgG level and the improvement of symptoms were dose-dependent. They speculate that the IgGs compete with the IgEs on the same antigen epitopes of the pollen, thereby providing a protective effect against rapid allergic reactions. The results of the clinical trial clearly indicate that the vaccine is capable of reducing the allergic response to future exposures to birch pollen. Valenta and his team also report fewer allergic side effects from the new vaccine. The authors indicate that hypoallergenic vaccines can be created with genetic engineering technology, or another recombinant DNA technology, to treat many common allergies known to affect more than 25% of the population in the industrialized world.

AustriaAustria

09.03.2012

Breast cancer patients who receive radiation therapy often suffer from inflammation linked to the treatment. Austrian Apeiron Biologics AG is now developing a topical superoxide dismutase treatment (APN201) to try to help these...

AustriaAustria

06.03.2012

The Paracelsus Private Medical University (PMU) in Salzburg is to build a new research center for spinal cord injuries. The €70m construction tab will be picked up by Dietrich Mateschitz, the owner of Red Bull. Other partners in...

AustriaAustria

16.12.2011

Vienna – Two big investors have poured €25m into Austrian vaccine specialist Affiris AG. Venture fund Santo VC – the investment vehicle of German biotech investors Thomas and Andreas Strüngmann – donated €20m, while the German...

AustriaAustria

08.11.2011

Vienna – In Affiris they trust – as a proof of their faith, two big investors poured €25 million into the Austrian developer of a possible Alzheimer drug. Venture fonds Santo VC, the investment vehicle of the German billionaires...

AustriaAustria

17.08.2011

Innsbruck – Austrian specialist for so-called ugimeres, Ugichem GmbH, has landed fresh funding. Along with V+ GmbH and the Austrian Research Promotion Agency, Swiss private investors invested about EUR2m to develop the first...

AustriaAustria

12.08.2011

Innsbruck – An Austrian physician has been fined EUR4,500 in a case involving a controversial stem cell therapy for incontinence. In early August, an Innsbruck Regional Court adjudged Hannes Strasser, who developed the method, at...

AustriaAustria

11.06.2011

Vienna – Nabriva Therapeutics AG, an Austrian specialist for the development of novel antibiotics, has achieved proof-of-concept for its first product in a clinical Phase II study. Called BC-3781, the compound is used to treat...

AustriaAustria

11.06.2011

Vienna – Nabriva Therapeutics AG, an Austrian specialist for the development of novel antibiotics, has achieved proof-of-concept for its first product in a clinical Phase II study. Called BC-3781, the compound is used to treat...

AustriaAustria

28.04.2011

Vienna - f-star, an antibody specialist, today announced the closing of aEUR 15 Million financing. The investment was led by SR One, the corporate venture capital arm of GlaxoSmithKline. All of f-star’s existing investors, Atlas...

Displaying results 1 to 10 out of 116

1-10 Next >

© 2007-2014 BIOCOM

http://www.european-biotechnology-news.com/news/messages-archive/archive-austria/article/hypoallergenic-vaccine-may-ease-birch-pollen-allergies.html

Image Gallery

Stock list

All quotes

TOP

  • GW PHARMACEUTICALS (UK)344.00 GBP12.6%
  • THERAMETRICS (CH)0.11 CHF10.0%
  • ACTIVE BIOTECH (S)35.60 SEK9.9%

FLOP

  • XENETIC BIOSCIENCES (UK)6.00 GBP-14.3%
  • GENFIT (F)22.42 EUR-8.1%
  • BAVARIAN NORDIC (D)13.63 EUR-6.4%

TOP

  • BIOTECH PHARMACON (N)19.00 NOK67.4%
  • WILEX (D)0.81 EUR37.3%
  • E-THERAPEUTICS (UK)28.00 GBP34.9%

FLOP

  • CYTOS (CH)0.16 CHF-94.1%
  • BIONOR PHARMA (N)2.17 NOK-45.7%
  • DIAGENIC (N)0.77 NOK-38.9%

TOP

  • SILENCE THERAPEUTICS (UK)257.25 GBP6331.2%
  • IXICO (UK)66.50 GBP734.4%
  • PLETHORA (UK)10.00 GBP614.3%

FLOP

  • CYTOS (CH)0.16 CHF-96.1%
  • EVOCUTIS (UK)0.22 GBP-91.9%
  • ADDEX (CH)1.96 CHF-71.0%

No liability assumed, Date: 24.04.2014

Current issue

All issues

Product of the week

Products

Events

All Events

Partner-Events

München

BioVaria 2014

Frankfurt am Main

7th DVFA Life Science Conference

White Paper